Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory

被引：0
|
作者：
Hristova, Mariyana [1 ]
机构：
[1] Med Ctr Varna, Div Endocrinol, Varna, Bulgaria
来源：
MEDICAL HYPOTHESES | 2017年 / 102卷
关键词：
TYPE-2; DIABETES-MELLITUS; METABOLIC SYNDROME; SGLT2; INHIBITORS; BLOOD-PRESSURE; KIDNEY-DISEASE; HYPOTHESIS; OUTCOMES; DAPAGLIFLOZIN; REABSORPTION; METAANALYSIS;
D O I：
10.1016/j.mehy.2017.02.021
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：61 / 64
页数：4
相关论文
共 50 条
  • [21] Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
    Nelson, Adam J.
    Harrington, Josephine L.
    Kolkailah, Ahmed A.
    Pagidipati, Neha J.
    McGuire, Darren K.
    HEART FAILURE CLINICS, 2022, 18 (04) : 597 - 607
  • [22] Sodium-Glucose Cotransporter-2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
    Porcari, Aldostefano
    Cappelli, Francesco
    Nitsche, Christian
    Tomasoni, Daniela
    Sinigiani, Giulio
    Longhi, Simone
    Bordignon, Luca
    Masri, Ahmad
    Serenelli, Matteo
    Urey, Marcus A.
    Musumeci, Beatrice
    Cipriani, Alberto
    Canepa, Marco
    Eslam, Roza Badr
    Kronberger, Christina
    Chimenti, Cristina
    Zampieri, Mattia
    Allegro, Valentina
    Razvi, Yousuf
    Patel, Rishi
    Ioannou, Adam
    Rauf, Muhammad U.
    Petrie, Aviva
    Whelan, Carol
    Emdin, Michele
    Metra, Marco
    Merlo, Marco
    Sinagra, Gianfranco
    Hawkins, Philip
    Solomon, Scott
    Gillmore, Julian
    Fontana, Marianna
    CIRCULATION, 2023, 148 (25) : E303 - E303
  • [23] Sodium-glucose cotransporter-2 inhibitors reduce risk of nephrolithiasis
    Di Lellis, Maddalena Angela
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (12) : 674 - 675
  • [24] Expanding Clinical Use of Sodium-glucose Cotransporter-2 Inhibitors?
    Dhawan, Richa
    Chaney, Mark A.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2024, 38 (10) : 2135 - 2138
  • [25] Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
    Xiang, Boyang
    Zhao, Xiaoya
    Zhou, Xiang
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [26] Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections
    Sarafidis, Pantelis
    Papagianni, Aikaterini
    ANNALS OF INTERNAL MEDICINE, 2019, 171 (12) : 943 - 944
  • [27] Sodium-glucose cotransporter-2 inhibitors in patients without diabetes
    Fryml, Elise
    Lanktree, Matthew B.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (17) : E619 - E619
  • [28] Sodium-glucose cotransporter-2 inhibitors reduce the risk of gout
    Pavlicek, Vojtech
    DIABETOLOGE, 2020, 16 (02): : 190 - 191
  • [29] Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
    Boyang Xiang
    Xiaoya Zhao
    Xiang Zhou
    Cardiovascular Diabetology, 20
  • [30] Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy
    Byer, Stefano H.
    Sivamurugan, Aravinthasamy
    Grewal, Udhayvir S.
    Fradley, Michael G.
    Dominic, Paari
    AMERICAN JOURNAL OF CARDIOLOGY, 2025, 243 : 15 - 18
12345